• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

How Do Alternative Antibiotics Regimens to Prevent Surgical Site Infection Following Cesarean Section compare to Cefazolin?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • First-line antibiotic to prevent surgical site infection following cesarean section is a first-generation cephalosporin like cefazolin
  • Alternative for penicillin allergy is clindamycin and aminoglycoside
    • This regimen has not been well studied
  • Kawakita et al. (Obstetrics & Gynecology, 2018) sought to determine surgical site infection in women undergoing cesarean section who received a non-cephalosporin antibiotic regimen

METHODS:

  • Retrospective cohort study
  • Participants
    • Women undergoing cesarean delivery (2012-2017)
    • ≥23 weeks
    • Labored, unlabored, and scheduled sections were all included
    • Women with chorioamnionitis were excluded
  • Patients were treated with either
    • Cefazolin IV (2 g or 3 g if BMI ≥40)
    • A standard alternative
      • Clindamycin IV (900 mg) and gentamicin (5 mg/kg)
      • Azithromycin (500 mg)
    • Inappropriate alternatives (such as clindamycin only)
  • Primary outcome: Composite of surgical site infections within 6 weeks after section including
    • Cellulitis | Endometritis | Deep wound infection | Abdominopelvic abscess | Sepsis
  • Secondary outcomes included
    • Hematoma and seroma | Wound dehiscence (greater than 1 cm) | Any main emergency department (ED) visit postpartum period | Main ED visit as a result of wound complication (infection, hematoma and seroma, or dehiscence) | Any hospital readmission occurring up to 6 weeks after surgery
  • Statistical analysis
    • Confounding was addressed using propensity score-adjusted logistic regression models

RESULTS:

  • 6,584 cases identified
    • Cefazolin: 6,163 (93.6%)
    • Standard alternative: 274 (4.2%)
    • Inappropriate alternatives: 147 (2.2%)
  • Use of standard alternative antibiotics compared with cefazolin was not associated with increased odds of the primary outcome
    • Crude odds ratio (OR) 1.50; 95% CI, 0.92–2.46
    • Adjusted OR 1.63; 95% CI, 0.97–2.60
  • Standard alternatives were associated with increased odds of cellulitis compared to cefazolin
    • Crude OR 2.07; 95% CI, 1.16–3.70
    • Adjusted OR 1.93; 95% CI, 1.03–3.31
    • Excluding women (1) who delivered after azithromycin was made available (2) with HIV or (3) who used illicit drugs resulted in similar findings
  • Use of inappropriate alternative antibiotics compared with cefazolin was associated with increased odds of
    • The primary outcome
      • Crude OR 4.37; 95% CI, 2.80–6.83
      • Adjusted OR 4.13; 95% CI, 2.59–6.36
    • Endometritis before discharge
      • Crude OR 6.85; 95% CI, 3.94–11.90
      • Adjusted OR 6.68; 95% CI, 3.69–11.44
    • Cellulitis
      • Crude OR 3.36; 95% CI, 1.78–6.34
      • Adjusted OR 3.23; 95% CI, 1.63–5.81

CONCLUSION:

  • Cefazolin was associated with a reduced risk of surgical site infections, compared to both standard and inappropriate alternatives
  • Inappropriate alternatives were especially problematic and associated with higher odds of wound complications
  • The authors note that only 10 to 20% of women who self-report β-lactam allergy truly have an allergy and they further state that

A thorough evaluation of patient-reported β-lactam allergy and adherence to ACOG-recommended antibiotic regimen may lower the rates of postcesarean surgical site infections. Further studies that examine alternatives to ACOG-recommended alternative antibiotics would be useful.

Learn More – Primary Sources:

Choice of Prophylactic Antibiotics and Surgical Site Infections After Cesarean Delivery

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

ACOG Guidance: Antibiotic Prophylaxis during Labor and Delivery
ACOG Guidance on Use of Sulfonamides and Nitrofurantoin for UTIs in the First Trimester
Updated Guidance on GBS Screening and Prophylaxis

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site